Page 6 - Adjuvant News Today

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) announced the CHMP of the European Medicines Agency has adopted a positive opinion recommending approval of KEYTRUDA, the company's anti-PD-1 therapy, as

Scientists found that a new combination adjuvant may boost the effectiveness of a number of inoculations.

SOUTH SAN FRANCISCO (dpa-AFX) - The US Food and Drug Administration has approved Roche's (RHHBY) Tecentriq or atezolizumab as adjuvant treatment, following surgery and platinum-based chemotherapy

-- Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting -- Approval is based on the Phase III IMpower010 study showing adjuvant ... | October 15, 2021

Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said the FDA has approved its Verzenio, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive

Chinese biotechnology company Clover Biopharmaceuticals said on Wednesday that a large trial shows its two-dose COVID-19 vaccine is 79 percent effective against the fast-spreading Delta variant, which was first detected in India.

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) said the FDA has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA as adjuvant therapy in certain patients

email article Patients with ultralow-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, a new analysis of a randomized trial showed. The 8-year breast cancer-specific survival (BCSS) was 99.2% among patients classified as clinically high-risk but ultralow-risk by the MammaPrint 70-gene assay. Patients with an ultralow-risk genomic assessment and low clinical risk had an 8-year BCSS of 9...

Similar OS, PFS, and patterns of recurrence, with more toxicity